Multiple Sclerosis (MS) care in low income countries is marked by significant disparities when compared to high income nations. While the global prevalence of the condition is rising, the infrastructure to diagnose and treat it has not kept pace in resource limited regions. In many low income settings, the journey from the first symptom to a confirmed diagnosis can take years due to a lack of specialized healthcare professionals and essential diagnostic equipment. Once a diagnosis is finally reached, patients often face a second hurdle: the near total absence of affordable, licensed disease modifying therapies (DMTs). This gap in care leads to faster disability progression and a higher socioeconomic burden on families who must often pay for medical costs out of pocket.
In 2026, the global health community is increasingly focused on narrowing this gap. Recent updates to the World Health Organization Essential Medicines List have begun to provide a framework for improving access, but structural barriers remain. From a severe shortage of neurologists to cultural stigmas that prevent people from seeking medical help, the experience of living with MS in a low income country is vastly different from that in the West. This article examines the specific obstacles found in these regions and the emerging strategies being used to provide life changing care in the face of limited resources.
What we will discuss in this article
- Severe diagnostic delays and misdiagnosis rates
- The scarcity of neurologists and specialized MS training
- Limited availability of MRI technology and laboratory tests
- Use of off label medications and essential medicine lists
- The financial impact of out of pocket healthcare costs
- Cultural stigma and its effect on treatment adherence
- Emergency guidance for acute neurological events
Diagnostic Challenges and Delays
In low income countries, the lack of awareness about MS symptoms among both the general public and primary care physicians is a primary barrier to early detection. Many people may live with symptoms for several years before receiving a correct diagnosis. This delay is often compounded by the fact that many other conditions common in these regions, such as tuberculosis or nutritional deficiencies, can mimic the early signs of MS.
A significant portion of patients in some regions are initially misdiagnosed, leading to inappropriate treatments and lost time for early intervention. While the 2017 McDonald criteria are the gold standard for diagnosis globally, less than half of low income countries consistently use them. This is primarily because the criteria rely heavily on Magnetic Resonance Imaging (MRI) and cerebrospinal fluid analysis, both of which are often inaccessible or prohibitively expensive for the average citizen.
Workforce and Infrastructure Disparities
The disparity in the number of trained neurologists is one of the most striking differences in care. High income countries may have over 8 neurologists per 100,000 people, whereas low income countries often have fewer than 0.05 per 100,000. This shortage means that the few available specialists are concentrated in urban centres, leaving rural populations with almost no access to specialised neurological care.
| Resource Category | High Income Countries | Low Income Countries |
| Neurologists | Median of 4.6 per 100,000 people | Median of 0.05 per 100,000 people |
| Licensed DMTs | Access to nearly all 20+ approved drugs | 70% have no or limited access |
| Diagnostic Tools | Universal access to high field MRI | Scarce machines and high out of pocket costs |
| National Registries | Common (supports research and care) | Rare (limited data on disease burden) |
Access to Treatment and the Role of Off Label Drugs
Access to disease modifying therapies (DMTs) is arguably the greatest divide in MS care. Approximately 7 in 10 low income countries have no access to licensed DMTs. Even when these drugs are registered in a country, their high cost often makes them unaffordable for the government health systems or individual patients.
To manage this crisis, many clinicians in low income regions rely on off label medications. These are drugs that were originally developed for other conditions, such as cancer or rheumatoid arthritis, but have shown benefit in MS.
- Rituximab: Frequently used as a high efficacy alternative to more expensive monoclonal antibodies.
- Azathioprine: A commonly used immunosuppressant that is more affordable but requires close monitoring for side effects.
- WHO Essential Medicines List: In a major step for global equity, the WHO added rituximab, cladribine, and glatiramer acetate to its list of essential medicines in 2023, providing a mandate for countries to make these treatments available at lower costs.
Socioeconomic and Cultural Factors
Living with MS in a low income setting often brings a heavy financial and social toll. In countries without universal healthcare or robust insurance, the cost of a single MRI or a month of medication can exceed a family’s total annual income. This leads to high rates of treatment non adherence, as patients are forced to prioritise basic necessities like food and housing over their medical needs.
Cultural stigma also plays a significant role. In many communities, neurological symptoms are misunderstood or attributed to mental illness or spiritual causes. This can lead to social isolation and a reluctance to seek medical help. Support networks and MS organisations are often less developed in these regions, leaving patients and their families to manage the psychological and physical burden of the disease with very little help.
Emergency Guidance
Regardless of the region or economic setting, certain neurological symptoms require immediate medical attention to prevent permanent disability. If you or someone you know experiences any of the following, seek emergency care immediately:
- Sudden and total loss of vision in one eye
- Severe new weakness that makes walking or standing impossible
- New and significant difficulty with breathing or swallowing
- Acute confusion or a sudden loss of consciousness
- Rapid and severe loss of coordination or balance
In these instances, contact local emergency services or visit the nearest available medical facility without delay.
To Summarise
Multiple Sclerosis care in low income countries is characterised by significant obstacles that are rarely seen in developed nations. The lack of neurologists and diagnostic equipment leads to years of delay in receiving a diagnosis. Treatment options are often limited to affordable off label medications due to the high cost of licensed therapies. While global initiatives and the inclusion of MS drugs on the WHO Essential Medicines List are positive steps, true equity in care will require continued investment in healthcare infrastructure and training. For now, the resilience of patients and the ingenuity of local healthcare providers remain the primary drivers of MS management in these challenging environments.
Why is MS often misdiagnosed in low income countries?
Misdiagnosis is common because MS symptoms can look like other infectious or nutritional diseases that are more prevalent in those regions, and there is often a lack of access to MRI scans to confirm the diagnosis.
Are off label drugs safe to use for MS?
Off label drugs like rituximab are widely used and have a strong evidence base for safety and effectiveness in MS, even if they were not originally developed specifically for the condition.
How can I find a neurologist in a low income region?
It is best to start at a major teaching hospital or a university medical centre, as specialised neurological resources are usually concentrated in these urban institutions.
Does the WHO Essential Medicines List actually help patients?
Yes, by including MS drugs on this list, the WHO encourages governments to include these treatments in their national health plans and negotiate lower prices with pharmaceutical companies.
Can diet and lifestyle help if I cannot access medication?
While lifestyle changes do not replace medication, maintaining a healthy diet and staying active can help manage symptoms like fatigue and improve overall well being when resources are scarce.
What is the biggest barrier to getting an MRI in a developing nation?
The biggest barriers are typically the physical scarcity of machines outside of capital cities and the high out of pocket cost for a single scan.
Are there support groups for MS in Africa or Southeast Asia?
Yes, several countries have national MS societies that are members of the Multiple Sclerosis International Federation and can provide local support and advocacy.
Authority Snapshot
This article was reviewed by Dr. Stefan Petrov, a UK-trained physician with an MBBS and extensive clinical experience in general medicine, surgery, and emergency care. Dr. Petrov has a background in managing acute medical cases and contributing to patient focused health education. This guide provides an evidence based overview of the global disparities in Multiple Sclerosis care, ensuring the information reflects current clinical realities and international health standards as of 2026.
